The study is designed to repeat an initial training set study conducted at Johns Hopkins
Medical Center, comparing a new investigational device, Indicor, a non-invasive tool for
estimating left ventricular end diastolic pressure (LVEDP), to the gold standard, invasively
measured LVEDP via direct measurement via left heart catheterization. The study is divided
into an initial training set, followed by the validation set which is designed to support an
FDA 510(k) submission and validate the final algorithm. Patients will be enrolled who are
scheduled to undergo a cardiac catheterization and will be asked to perform three tests with
the Indicor.

In Denmark, around 2 % of the population live with severe mental disease. People with severe
mental disease live 15-20 years less than the general population. The majority of the years
of life lost are a consequence of the excess mortality due to somatic disease. The high
prevalence of somatic disease among people with severe mental disease can be largely
attributed to physical inactivity, unhealthy diet and side effects from psychopharmacological
drugs. Apart from the impacts of unhealthy lifestyle and medication side effects, research
suggests that individuals with severe mental disease do not receive the same treatment for
their somatic diseases as do the rest of the population. The inequality in diagnostics and
treatment can be attributed to stigmatization from healthcare providers and patients' lacking
awareness of symptoms and reluctance to seek medical care. Further, the increasing
specialization within both somatic and psychiatric care has led to a division between these
two treatment systems (8,9). Patients with severe mental disease who simultaneously have one
or more somatic diseases need their treatment to be coordinated; such treatment should span
general practice, the municipality and the psychiatric and somatic hospital. Accordingly, the
following elements are necessary to create effective and coordinated treatment trajectories:
detailed preparation, qualitative process evaluation as an integrated part of the courses of
treatment, and involvement of all stakeholders from the start.
The overall aim of the project is to optimize the detection of selected chronic somatic
diseases, including cardiovascular disease (ischaemia and heart failure), diabetes,
hypertension and high cholesterol, in individuals with schizophrenia, schizoaffective
disorder or bipolar disorder; to initiate medical treatment; and to ensure treatment
compliance among patients.
Accordingly, the project has the following objectives:
- To develop an intervention targeting individuals with schizophrenia, schizoaffective
disorder or bipolar disorder that can optimize the detection of selected chronic somatic
diseases, including cardiovascular disease (ischaemia and heart failure), diabetes,
hypertension and high cholesterol
- To test whether the developed intervention can optimize the detection of cardiovascular
disease (ischaemia and heart failure), diabetes, hypertension and high cholesterol in
individuals with schizophrenia, schizoaffective disorder or bipolar disorder
The project's hypotheses are that an interdisciplinary and intersectoral intervention
targeting individuals with schizophrenia, schizoaffective disorder or bipolar disorder can
- optimize detection of cardiovascular diseases (ischaemia and cardiac insufficiency),
diabetes, hypertension and high cholesterol by systematic screening in general practice
- lead to initiation and maintenance of relevant medical treatment. Moreover, we
hypothesize that the complete intervention in a long-term perspective will lead to
decreased mortality within the target group.

Serum uric acid level is a commonly measured biomarker. The association between serum uric
acid level and the risk of developing cardiovascular diseases has been observed in some
studies, while others showed controversial results. Estimation of this association may help
to predict cardiovascular outcomes and may guide new treatment strategies. The hypothesis is
that increased serum uric acid level is associated with a range of cardiovascular diseases.

This study occurs in two phases. Phase 1 involves initial item development and measurement
validation of a new tool for identifying hospitalized patients at high risk for preventable
readmission. Primary tasks include item construction and content validation, data collection,
analysis, and instrument refinement. Phase 2 involves administering the refined instrument to
a new group of patients to determine final item content for the instrument, its factor
structure, and its predictive validity.

Mitochondrial dysfunction has been implicated in heart failure (HF), and is associated with
an imbalance in intracellular ratio of reduced nicotinamide-adenine dinucleotide (NADH) to
oxidized nicotinamide-adenine dinucleotide (NAD), or the NADH/NAD ratio. In mouse models of
HF, we have found that normalization of the NADH/NAD, through supplementation with NAD+
precursors, is associated with improvement in cardiac function. This Study will randomize
participants with systolic HF (ejection fraction ≤40%) to treatment with the NAD precursor,
nicotinamide riboside (NR) or matching placebo, uptitrated to a final oral dose of 1000mg
twice daily, to determine the safety and tolerability of NR in participants with systolic HF.

This is a prospective cohort study of patients with Heart Failure with an eighteen-month
follow-up aimed to collect all demographic, clinical, biological and para-clinical data to
study population characteristics, assess prognosis markers and occurrence of HF treatment
side effects.
Congestive Heart failure is a frequent pathology and its prevalence increases with age. Its
prognosis stays pejorative despite years of major therapeutical progress. In recent trials,
all-cause mortality rates at 1-year reach up to 20% and 50% at 5 years.
Medical care of congestive heart failure is based on precise international recommendations.
The association of Beta-Blockers, renin-angiotensin system blockers, mineralocorticoid
receptor antagonists, represent the basis of the pharmacological treatment.
Cardiac resynchronization treatment and implantable cardioverter-defibrillator are additional
efficient treatments that reduce events in appropriately selected patients.
Despite these improvements, the prognostic of congestive heart failure in registers is worse
than those observed in randomized trials. This can be explained by differences in congestive
heart failure patient populations and/or by a less rigorous medical care where treatments are
not optimized.
The evaluation of medical care in congestive heart failure is today of utmost importance.
Integrating new pharmacological molecules, medical devices and the application of new
recommendations have major interest for documentation and practical changes.
The main objective of this cohort will be to evaluate the evolution of the 12-month quality
of life score of a HF patient and the characteristics and treatments associated with it.

Almost 40,000 people in the United Kingdom receive a new pacemaker annually. Because the
pacemaker does not use the heart's normal conduction system, electrical activity from the
pacemaker spreads more slowly, disturbing the timing of the heart's contraction, which can
lead to heart muscle weakness and heart failure (HF).
Those with the greatest requirement for a pacemaker and highest percentage of pacemaker beats
are those at highest risk of heart muscle weakness.
This pilot study will be in two stages. Patients will be approached after their pacemaker
implant. Allocation to all treatment arms will be at random.
At the normal 6w visit, all participants will undergo cardiac ultrasound, blood tests and
complete a quality of life questionnaire. Participants will be allocated to optimal pacemaker
programming (to limit pacemaker heartbeats) or standard care. Those allocated optimal
programming will return 3m after the implant and those still needing a high proportion of
pacemaker beats, will be asked to have a cardiac magnetic resonance (CMR) scan and will be
randomly allocated to an angiotensin converting enzyme inhibitor (ACE inhibitor) a common
treatment for blood pressure and HF or not. After another 6m all will undergo heart
ultrasound, blood test and quality of life assessment, and where relevant, a second CMR scan.

The purpose of this study is to gather information on the safety and effectiveness of cardiac
resynchronization therapy (CRT) in patients who have mild heart failure (HF) and left bundle
branch block (LBBB).

Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.

Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.

Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.

Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.

Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.

Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

The data & information found on this website is provided “AS IS” from ClinicalTrials.gov.
Neither we, the United States Government, U.S. Department of Health and Human Services, National Institutes of Health, National Library of Medicine, nor any of its agencies, contractors, subcontractors or employees of the United States Government make any warranties, expressed or implied, with respect to data found on this site, and, furthermore, assume no liability, or the results of such use, of any part of the data.